Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Michael Birrer to Carcinoma

This is a "connection" page, showing publications Michael Birrer has written about Carcinoma.

 
Connection Strength
  
 
 
1.573
  
  1. Annunziata CM, Birrer MJ. CD157 in ovarian carcinoma: how does it help us? J Natl Cancer Inst. 2010 Aug 04; 102(15):1104-5.
    View in: PubMed
    Score: 0.335
  2. Na YJ, Farley J, Zeh A, del Carmen M, Penson R, Birrer MJ. Ovarian cancer: markers of response. Int J Gynecol Cancer. 2009 Dec; 19 Suppl 2:S21-9.
    View in: PubMed
    Score: 0.321
  3. Birrer MJ. Ovarian cancer: not a borderline issue! Cancer Biol Ther. 2006 Jul; 5(7):786-7.
    View in: PubMed
    Score: 0.254
  4. Birrer MJ. Translational research and epithelial carcinogenesis: molecular diagnostic assays now--molecular screening assays soon? J Natl Cancer Inst. 1995 Jul 19; 87(14):1041-3.
    View in: PubMed
    Score: 0.119
  5. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012 Jul 20; 30(21):2654-63.
    View in: PubMed
    Score: 0.096
  6. del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol. 2012 Sep; 126(3):481-90.
    View in: PubMed
    Score: 0.095
  7. Ledermann JA, Marth C, Carey MS, Birrer M, Bowtell DD, Kaye S, McNeish I, Oza A, Scambia G, Rustin G, Stehman FB, Gershenson D, Thomas G, Berns E, Casado A, Ottevanger N, Hilpert F, Kim BG, Okamoto A, Bacon M, Kitchener H, Stuart GC. Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. Int J Gynecol Cancer. 2011 May; 21(4):763-70.
    View in: PubMed
    Score: 0.089
  8. Anglesio MS, Arnold JM, George J, Tinker AV, Tothill R, Waddell N, Simms L, Locandro B, Fereday S, Traficante N, Russell P, Sharma R, Birrer MJ, deFazio A, Chenevix-Trench G, Bowtell DD. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res. 2008 Nov; 6(11):1678-90.
    View in: PubMed
    Score: 0.075
  9. Landen CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008 Feb 20; 26(6):995-1005.
    View in: PubMed
    Score: 0.070
  10. Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L, Bonome T, Birrer MJ, Berkowitz RS, Wong KK. Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers. 2007; 23(5-6):367-76.
    View in: PubMed
    Score: 0.066
  11. Taylor RR, Teneriello MG, Nash JD, Park RC, Birrer MJ. The molecular genetics of gyn malignancies. Oncology (Williston Park). 1994 Oct; 8(10):63-70, 73; discussion 73, 78-82.
    View in: PubMed
    Score: 0.028
  12. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, Birrer MJ. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 1993 Jul 01; 53(13):3103-8.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.